This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Zymeworks (ZYME), Celldex (CLDX) and ACADIA Pharmaceuticals (ACAD)

Tipranks - Tipranks - Wed Jul 1, 4:22AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Zymeworks (ZYME), Celldex (CLDX) and ACADIA Pharmaceuticals (ACAD) with bullish sentiments.

End of Quarter Sale - 70% Off

Zymeworks (ZYME)

In a report released yesterday, Eva Fortea Verdejo from Wells Fargo maintained a Buy rating on Zymeworks, with a price target of $37.00. The company’s shares closed last Monday at $24.10.

According to TipRanks.com, Verdejo is a 5-star analyst with an average return of 51.8% and a 75.7% success rate. Verdejo covers the Healthcare sector, focusing on stocks such as Zentalis Pharmaceuticals, Bicara Therapeutics Inc., and Kiniksa Pharmaceuticals. ;'>

Zymeworks has an analyst consensus of Strong Buy, with a price target consensus of $37.33, implying a 60.8% upside from current levels. In a report issued on June 18, Truist Financial also maintained a Buy rating on the stock.

See the top stocks recommended by analysts >>

Celldex (CLDX)

Wells Fargo analyst Derek Archila reiterated a Buy rating on Celldex yesterday and set a price target of $54.00. The company’s shares closed last Monday at $37.44.

According to TipRanks.com, Archila is a 5-star analyst with an average return of 22.1% and a 57.3% success rate. Archila covers the Healthcare sector, focusing on stocks such as First Tracks Biotherapeutics Inc, Kyverna Therapeutics, Inc., and Arvinas Holding Company. ;'>

Celldex has an analyst consensus of Strong Buy, with a price target consensus of $51.10, implying a 44.7% upside from current levels. In a report issued on June 14, Wolfe Research also maintained a Buy rating on the stock with a $44.00 price target.

ACADIA Pharmaceuticals (ACAD)

In a report released yesterday, Tazeen Ahmad from Bank of America Securities reiterated a Buy rating on ACADIA Pharmaceuticals, with a price target of $30.00. The company’s shares closed last Monday at $25.20.

According to TipRanks.com, Ahmad is a 5-star analyst with an average return of 9.0% and a 62.3% success rate. Ahmad covers the Healthcare sector, focusing on stocks such as Aardvark Therapeutics, Inc., Ultragenyx Pharmaceutical, and Bicara Therapeutics Inc. ;'>

Currently, the analyst consensus on ACADIA Pharmaceuticals is a Moderate Buy with an average price target of $32.43, a 27.7% upside from current levels. In a report released yesterday, TipRanks – OpenAI also upgraded the stock to Buy with a $28.00 price target.

Read More on ZYME:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).